SynthesisJournal of the European Academy of Dermatology and Venereology : JEADV2025
Virulence and resistance factors of Nakaseomyces glabratus (formerly known as Candida glabrata) in Europe: A systematic review.
Synthesis in Journal of the European Academy of Dermatology and Venereology : JEADV, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Antifungal Resistance of Candida spp. Isolates From HIV/AIDS Patients in Iran 1999-2024: A Systematic Review and Meta-Analysis.Journal of clinical laboratory analysis · 2025Pooled it
- Virulence and resistance factors of Nakaseomyces glabratus (formerly known as Candida glabrata) in Europe: A systematic review.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Pooled it
- Anandamide Targets Membrane Integrity in Non-Journal of fungi (Basel, Switzerland) · 2026Article
- WHO Critical- and High-Priority Fungal Pathogens Beyond Human Medicine: Expanding One Health Surveillance.Pathogens (Basel, Switzerland) · 2026Article
- A combined approach using environmental yeasts and microbial indicators to assess aquatic pollution.Environmental monitoring and assessment · 2026Article
- Nano-Encapsulated Cinnamomum cassia Essential Oil in Combination With Fluconazole Exhibits Synergistic Activity Against Fluconazole-Resistant Nakaseomyces glabratus and Pichia kudriavzevii.Veterinary medicine and science · 2026Article
- Establishment and application of a duplex RPA-LFS detection system for Candida glabrata and Candida krusei.Scientific reports · 2026Article
- Cryo-EM structure of bixafen-bound S. cerevisiae complex II unravels SDHI specificity against pathogenic fungi.Communications biology · 2026Article
- Unveiling the diversity, ecology, and biotechnological potential of culturable marine yeasts in Western Mediterranean coastal ecosystems.IMA fungus · 2026Article
- Mechanism of azole resistance inJournal of medical microbiology · 2025Article
- Biochemical and Physiological Profiles ofLife (Basel, Switzerland) · 2025Article
- Article
- Review
- The conundrum of antifungal resistance: Emergence of Nakaseomyces glabratus (Candida glabrata) in Europe with global implications.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Article
- Molecular Characterization of Culturable Yeasts and Nonspore-Forming Bacteria Associated With Fermented Kapok Seeds (International journal of food science · 2025Article
- New antifungal strategies and drug development against WHO critical priority fungal pathogens.Frontiers in cellular and infection microbiology · 2025Review
- Clinical manifestations and treatment of candidemia caused by different Candida species: a retrospective study.BMC infectious diseases · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNakaseomyces glabratus (N. glabratus) formerly known as Candida glabrata (C. glabrata), is an endogenous opportunistic pathogen, which is generally located in the gastrointestinal tract but can spread in immunocompromised patients. N. glabratus is the second most common pathogen that causes candidemia in several countries. N. glabratus virulence factors may increase antifungal resistance and reduce the number of available treatment options. High resistance to azoles and increasing resistance to echinocandins have been previously reported in N. glabratus.
objectiveTo establish the distribution of N. glabratus isolates in Europe and its drug susceptibility/resistance in each country over the last 7 years.
methodsThe search was performed across three databases: PubMed, Scopus and Scielo, using the MeSH terms: "Candida glabrata", "Nakaseomyces glabratus", "Europe", "resistance" and "Epidemiology" exclusively in English. All available information from January 2002 to December 2022 was included, excluding reviews, meta-analyses and book chapters.
resultsFifty-seven articles with information on antifungal susceptibility in Europe were retrieved and analysed with a total of 15,400 reported C. glabrata isolates. Remarkably, nations that presented the maximum number of cases during the study period included the United Kingdom (n = 7241, 47.02%), France (n = 3190, 20.71%), Spain (n = 900, 5.84%), Hungary (n = 745, 4.84%) and Italy (n = 486, 3.16%). C. glabrata isolates presented resistance to azoles [voriconazole (n = 2225, 14.45%), fluconazole (n = 1612, 10.47%), itraconazole (n = 337, 2.19%) and clotrimazole (n = 89, 0.58%)], increased resistance to echinocandins, especially to anidulafungin (n = 138, 0.89%), and high sensitivity to amphotericin B.
conclusionsThe number of candidemia cases associated with triazole-resistant N. glabratus isolates have been increasing in Europe. Therefore, echinocandins and amphotericin B can be considered optional empirical treatments; however, antifungal susceptibility testing is required to determine the best therapeutic options.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.